Study On The Correlation Between Serum Neurofilament Light Chain Protein And Marrow Sea Deficiency Syndrome In Alzheimer’s Disease

Objective:To study whether serum neurofilament light chain protein is related to Alzheimer’s disease,and to further explore whether serum neurofilament light chain protein can be used as a peripheral blood biomarker to predict the early stage of Alzheimer’s disease.Methods:Using a case-control study,Select 50 patients with Alzheimer’s disease(AD)from the Alzheimer’s disease clinical database of the Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University,50 patients with mild cognitive impairment(MCI)and select the same time period 50 healthy control group(CN)patients matched by age and education level.The subjects were all collected serum and detected the serum NFL protein level by enzyme-linked immunosorbent assay(ELISA),and SPSS23.0 was used for statistical analysis.Results:(1)The AD group,MCI group and CN group have no statistical difference in age,education years,and BMI(P>0.05),and the data are comparable.The AD group,MCI group and CN group MMSE,MOCA,ADL,CDR scale score have significant differences(P=0.000),which is statistically significant.(2)The NFL level in the AD group was(4.486±2.463)ng/ml,the NFL level in the MCI group was(5.101±2.172)ng/ml,and the NFL level in the CN group was(2.885±1.469)ng/ml.The NFL protein level of AD group and MCI group was significantly higher than that of CN group(P<0.05),and the NFL protein level of MCI group was the highest.There was a statistical difference between three groups(P=0.000).(3)Spearman correlation analysis found that age,MMSE score,MOCA score,ADL score and CDR score were not correlated with NFL protein levels among the three groups(P>0.05).Conclusion: Serum neurofilament light chain protein is related to Alzheimer’s disease,and its protein level is the highest in patients with mild cognitive impairment,suggesting that serum neurofilament light chain may be a peripheral blood biomarker for early diagnosis of Alzheimer’s disease.